 |
| |
DNAvaccine.com mailing list
To get on the DNAvaccine.com mailing list, please email me at peratt@aldevron.com . The mailing list is a good way to find out the latest information about new technology, upcoming conference, or just general information that you may find resourceful for your day to day experiments.
I hope to hear from you soon. |
|
|
Vical Reports First Quarter 2008 Financial Results and Updates Key Development Programs
|
|
Posted by administrator on Thursday, May 08 @ 11:57:55 PDT (10 reads)
Vical had cash and investments of $60 million at March 31, 2008. The
company's first quarter 2008 financial results were consistent with its
projection for a full year net loss of between $32 million and $37 million
and a net cash burn of $27 million to $32 million.
Read More...
(Read More... | Score: 0)
|
|
DOR BioPharma Acquires Option for Anthrax Vaccine
|
|
Posted by administrator on Thursday, May 08 @ 11:45:43 PDT (9 reads)
The option, which was obtained through Harvard University's Office of Technology Development, involves an issued U.S. patent that covers variants of an antigen developed in a Harvard Medical School laboratory, according to DOR.
Read More...
(Read More... | Score: 0)
|
|
Novartis Corporation Menveo Vaccine Shows Superior Immune Response
|
|
Posted by administrator on Tuesday, May 06 @ 10:51:09 PDT (23 reads)
These data build on previous studies that demonstrated Menveo generates a strong protective immune response against these four vaccine-preventable serogroups in people across age groups from infancy to adulthood. Novartis expects to submit a Biologics License Application (BLA) to the US Food and Drug Administration later this year.
Read More...
(Read More... | Score: 0)
|
|
Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
|
|
Posted by administrator on Monday, May 05 @ 08:31:04 PDT (17 reads)
Researchers from the University of Pittsburgh and the U.S. Centers for
Disease Control and Prevention will report progress toward a DNA vaccine
against highly contagious and deadly avian influenza (influenza A/H5N1) in
poultry.
Read More...
(Read More... | Score: 0)
|
|
MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
|
|
Posted by administrator on Monday, May 05 @ 04:38:09 PDT (20 reads)
“Approval for the MGN1703 study is a great success which rewards our intensive efforts in this field“, said Dr Matthias Schroff, CEO of MOLOGEN AG. “We now have the chance to demonstrate the great potential for dSLIM® as an innovative form of cancer therapy.”
Read More...
(Read More... | Score: 0)
|
| |
| |
